IOVA Stock Analysis: Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04,
- Latest close
- $14.22
- 20-day change
- +63.45%
- Trend state
- BULLISH
- Classification
- Healthcare · Biotechnology
Market context
Iovance Biotherapeutics, Inc. moved +63.45% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $263.5M revenue · -$391M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.7/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.